AstraZeneca invests additional $136 million to expand Qingdao inhalants facility
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Subscribe To Our Newsletter & Stay Updated